Input Symbol:

Show Other Options & Instructions

Month Back:
Owned(%):
Shares Outstanding(‱)
Transaction Code:

Instructions

Month Back: Display transaction record of previous n months.

Owned(%): Transaction shares relative to shares owned.

Shares Outstanding(‱): Transaction shares relative to shares outstanding.

Check Insider Trading for more details.

upgrade to Tier 1 to access blurred content, display up to 300 records, and unlimited CSV download

Data last updated 2024-04-28 04:05:40 -0500 US CDT

Insider Sentiment

Company Name Sector Industry Shares Outstanding(Mil) 52-week High/Low Period Acq/Dsp Transaction Countb Ids/Sec/Mkt Quantc Acq/Dsp Shares Amountb Acq/Dsp PctSOd
Vanda Pharmaceuticals Inc. Health Care Pharmaceuticals 57.54
3.3
7.0
4.6
 3-month 0 / 5
0 / 121098
0.0 / 0.2
6-month 0 / 5
0 / 121098
0.0 / 0.2

Data last updated 2024-04-27 07:55:23 -0500 US CDT

Major Shareholders

Shareholder Relation Report Date Holding Pct Sharesa Shares(Previous Report Date)a Transactions (3 month)b Transactions (6 month)b
Flynn James E Possible Member of 10% Group 2016-09-26 7.5% 4328344 (-20.5%, NA%) 5448805 (2016-09-19)
Polymeropoulos Mihael Hristos President and CEO, Chairman of the Board 2024-03-06 3.3% 1871730 (-2.8%, NA%) 1926902 (2024-02-21)
C: 0 / 1
S: 0 / 55172
P: NA / 4.19
C: 0 / 1
S: 0 / 55172
P: NA / 4.19
Birznieks Gunther SVP, Business Development 2024-03-06 0.5% 313569 (-5.2%, NA%) 330980 (2024-02-21)
C: 0 / 1
S: 0 / 17411
P: NA / 4.21
C: 0 / 1
S: 0 / 17411
P: NA / 4.21
Moran Kevin Patrick SVP, CFO & Treasurer 2024-03-06 0.4% 231649 (-5.9%, 90.9%) 246349 (2024-02-21)
C: 0 / 1
S: 0 / 14700
P: NA / 4.31
C: 0 / 1
S: 0 / 14700
P: NA / 4.31
Williams Timothy SVP & General Counsel 2024-03-06 0.3% 196825 (-7.9%, 121.4%) 213913 (2024-02-21)
C: 0 / 1
S: 0 / 17088
P: NA / 4.29
C: 0 / 1
S: 0 / 17088
P: NA / 4.29
Kelly James Patrick EVP & Chief Financial Officer 2020-03-04 0.3% 186869 (-9.1%, NA%) 205726 (2020-01-06)
Reverberi Gian Piero SVP & Chief Commercial Officer 2020-03-04 0.3% 165384 (-0.8%, NA%) 166834 (2020-01-06)
Wijkstrom Joakim SVP, Chief Marketing Officer 2024-03-06 0.2% 129789 (-11.3%, 14.0%) 146516 (2024-02-21)
C: 0 / 1
S: 0 / 16727
P: NA / 4.3
C: 0 / 1
S: 0 / 16727
P: NA / 4.3
Gulino Richard L. SVP, General Counsel & Sec. 2018-03-02 0.2% 115073 (29.7%, NA%) 88733 (2018-01-04)
Dugan Richard W Director 2023-06-12 0.2% 97700 (21.5%, NA%) 80393 (2022-06-21)
Honore Tage Director 2023-06-12 0.1% 43715 (65.5%, NA%) 26408 (2023-03-17)
Chrousos Phaedra Director 2023-06-12 0.1% 42238 (69.4%, NA%) 24931 (2022-06-21)
Ward Anne Sempowski Director 2023-06-12 0.1% 39313 (78.6%, NA%) 22006 (2022-06-21)
Mitchell Stephen Ray Director 2023-08-11 0.1% 29328 (-18.0%, NA%) 35828 (2023-06-12)

a Total of direct and indirect accounts with percentage change comparing with (previous report, 3 months ago). The latter is NA when no change was found in the last 3 months.
Notice: Shares amount and percentage change 1) do not reflect intraday conversion and execution of derivative securities. 2) may subject to correction on amendment filing.
b Vital&Spontaneous transactions of the past 3 and 6 months, respectively. For acquisitions, code P (open market purchase), L (small acquisition), and I (at discretion of broker) are counted. For dispositions, code S (open market sell), D (sell back to issuer) and I (at discretion of broker) are counted. "C:" count of number of transactions. "S:" shares amount involved in corrresponding transactions. "P:" average per share price of the transactions (for reference only). Horizontal bar chart denotes shares amount of acquisitions and dispositions. Black thin bar is fixed size ruler for easy comparison between reporters.
c Quantile value of transaction count in b among industry peers, sector peers, and the market, respectively.
d Percentage of transaction shares amount to shares outstanding.
Notice: red exclamation mark (!) represents the reporter has Form 4 amendment filings in the latest three reports.

Non-derivative Transactions Chart

Tips: Click legend to show single series     Click any bar to highlight corresponding transaction records      what is this?




Non-derivative Transactions Table      CSV download

Tips: type "code_p" to show transactions with code "P".

Filing Date Transaction Date Operation Date Original Filing Reporter Relation Opr Amounta %(Owned)b ‱(SO)c Avg Prcd Account Type Full Name Code Remain Shares Outstanding (Million)e
2024-03-06 2024-03-04 2024-03-04 to 2024-03-05 4 Birznieks Gunther SVP, BUSINESS DEVELOPMENT dsp 17411.0 5.26 3.03 4.21 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_S

code  S 		313569.0 thumbnail 57.54 (VNDA)
2024-03-06 2024-03-04 2024-03-04 to 2024-03-05 4 Williams Timothy SVP & GENERAL COUNSEL dsp 17088.0 7.99 2.97 4.29 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_S

code  S 		196825.0 thumbnail 57.54 (VNDA)
2024-03-06 2024-03-04 2024-03-04 to 2024-03-05 4 Polymeropoulos Mihael Hristos PRESIDENT AND CEO, CHAIRMAN OF THE BOARD dsp 55172.0 2.86 9.59 4.19 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_S

code  S 		1871730.0 thumbnail 57.54 (VNDA)
2024-03-06 2024-03-04 2024-03-04 to 2024-03-05 4 Moran Kevin Patrick SVP, CFO & TREASURER dsp 14700.0 5.98 2.55 4.31 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_S

code  S 		231014.0 thumbnail 57.54 (VNDA)
2024-03-06 2024-03-04 4 Moran Kevin Patrick SVP, CFO & TREASURER holding 635.0 0 0.11 0.0 By Wife Common Stock VANDA PHARMACEUTICALS INC.

code_

NA 		57.54 (VNDA)
2024-03-06 2024-03-04 2024-03-04 to 2024-03-05 4 Wijkstrom Joakim SVP, CHIEF MARKETING OFFICER dsp 16727.0 11.42 2.91 4.3 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_S

code  S 		129789.0 thumbnail 57.54 (VNDA)
2024-02-21 2024-02-16 2024-02-16 4 Williams Timothy SVP & GENERAL COUNSEL acq 125000.0 58.43 21.72 0.0 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_A

code  A 		213913.0 57.54 (VNDA)
2024-02-21 2024-02-16 2024-02-16 4 Moran Kevin Patrick SVP, CFO & TREASURER acq 125000.0 50.87 21.72 0.0 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_A

code  A 		245714.0 57.54 (VNDA)
2024-02-21 2024-02-16 4 Moran Kevin Patrick SVP, CFO & TREASURER holding 635.0 0 0.11 0.0 By Wife Common Stock VANDA PHARMACEUTICALS INC.

code_

NA 		57.54 (VNDA)
2024-02-21 2024-02-16 2024-02-16 4 Polymeropoulos Mihael Hristos PRESIDENT AND CEO, CHAIRMAN OF THE BOARD acq 450000.0 23.35 78.21 0.0 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_A

code  A 		1926902.0 57.54 (VNDA)
2024-02-21 2024-02-16 2024-02-16 4 Wijkstrom Joakim SVP, CHIEF MARKETING OFFICER acq 32700.0 22.32 5.68 0.0 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_A

code  A 		146516.0 57.54 (VNDA)
2024-02-21 2024-02-16 2024-02-16 4 Birznieks Gunther SVP, BUSINESS DEVELOPMENT acq 125000.0 37.77 21.72 0.0 Direct Common Stock VANDA PHARMACEUTICALS INC.

code_A

code  A 		330980.0 57.54 (VNDA)

Derivative Transactions Chart

Tips: Click legend to show single series     Click any bar to highlight corresponding transaction records      what is this?






Derivative Transactions Table

Tips: type "code_m" to show transactions with code "M".

Filing Date Transaction Date Operation Date Original Filing Reporter Relation Opr Amounta %(Owned)b ‱(SO)c Avg Prcd Account Type Full Name Code Remain Shares Outstanding (Million)e
Form 3      CSV download
Filing Date Date requiring statement Form Type Reporter Relation Amounta ‱(SO)c Avg Excercisable Prcd Account Type Full Name Shares Outstanding (Million)e

a Sum of same type of securities in the form
b Relative to reporter's shares owned before (disposition) or after (acquisition) operation
c Relative to issuer's shares outstanding (1/10000)
d Average price for securities of the same type. Check the original form for detailed prices of multiple transactions
e Documented shares outstanding closest to the transaction date
Note: Corporate may change mapped CIK when merge or spin-off happen. Please report error if the ticker you searched for does not have up-to-date insider trading information.
Show up to 30 records per table for current tier. (Access Guide)